Decision making about prophylactic oophorectomy among at-risk women: Psychological influences and implications

Gynecologic Oncology

Volumn 75, Issue 3, 1999, Pages 406-412

  Miller, Suzanne M ^a   Fang, Carolyn Y ^a   Manne, Sharon L ^a   Engstrom, Paul F ^a   Daly, Mary B ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Monitoring vs blunting; Ovarian cancer risk; Prophylactic oophorectomy

Indexed keywords

ARTICLE; COGNITION; FAMILY HISTORY; FEMALE; HUMAN; HUMAN TISSUE; INFORMATION PROCESSING; OVARIECTOMY; OVARY CANCER; PATIENT COUNSELING; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RISK MANAGEMENT;

EID: 0032785847     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5611     Document Type: Article

References (83)

1. Gallion H HS, Smith S A. Hereditary ovarian carcinoma. Semin Surg Oncol. 10:1994;249-254.
2. J Am Med Assoc. 273:1995;491-497.
3. Hoskins W J. Prospective on ovarian cancer: why prevent? J Cell Biochem Suppl. 23:1995;189-199.
4. Averette H E, Nguyen H N. The role of prophylactic oophorectomy in cancer prevention. Gynecol Oncol. 55:1994;S38-S41.
5. Sightler S E, Boike G M, Estape R E, Averette H E. Ovarian cancer in women with prior hysterectomy: A 14-year experience at the University of Miami. Obstet Gynecol. 78:1991;681-684.
6. Daly M, Lerman C. Ovarian cancer risk counseling: a guide for the practitioner. Oncology. 7:1993;27-34.
7. Nguyen H N, Averette H E, Janicek M. Ovarian carcinoma. A review of the significance of familial risk factors and the role of prophylactic oophorectomy in cancer patients. Cancer. 74:1994;545-555.
8. Struewing J P, Watson P, Easton D F, Ponder B AJ, Lynch H T, Tucker M A. Prophylactic oophorectomy in inherited breast/ovarian cancer families. Monogr Natl Cancer Inst. 17:1995;33-35.
9. American Cancer Society, Cancer facts and figures - 1999, Atlanta, GA, American Cancer Society, 1999.
10. Morgan R J, Copeland L, Gershenson D, Locker G, McIntosh D, Ozols R, Teng N. NCCN ovarian cancer practice guidelines. The National Comprehensive Cancer Network. Oncology. 10:1996;293-310.
11. Silva I S, Swerdlow A J. Recent trends in incidence of and mortality from breast, ovarian, and endometrial cancers in England and Wales and their relation to changing fertility and oral contraceptive use. Br J Cancer. 72:1995;485-492.
12. Gross T P, Schlesselman J J. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol. 83:1994;419-424.
13. Green A. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Study Group. Int J Cancer. 71:1997;948-951.
14. Cornelison T L. Tubal ligation and the risk of ovarian carcinoma. Cancer Detect Prev. 21:1997;1-6.
15. Narod S A, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Brunet J S, Ponder B AJ, Klijn J GM. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med. 339:1998;424-444.
16. Schlesselman J J. Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstet Gynecol. 85:1995;793-801.
17. Rosenberg L, Palmer J R, Rao R S, Zauber A G, Strom B L, Warshauer M E, Harlap S, Shapiro S. Case-control study of oral contraceptive use and risk of breast cancer. Am J Epidemiol. 143:1996;25-37.
18. Ursin G, Henderson B E, Haile R W, Pike M C, Zhou N, Diep A, Bernstein L. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res. 57:1997;3678-3681.
19. Brinton L A, Brogan D R, Coates R J, Swanson C A, Potischman N, Stanford J L. Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy. Menopause. 5:1998;145-151.
20. Burke W, Daly M, Garber J. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. J Am Med Assoc. 277:1997;997-1003.
21. Klijn J GM. Should prophylactic surgery be used in women with a high risk of breast cancer? Eur J Cancer. 33:1997;2149-2159.
22. Rozario D, Brown I, Fung M F, Temple L. Is incidental prophylactic oophorectomy an acceptable means to reduce the incidence of ovarian cancer? Am J Surg. 173:1997;495-498.
23. Piver M S, Jishi M F, Tsukada Y, Navas G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. Cancer. 71:1993;2721-2755.
24. Schrag D, Kuntz K M, Garber J E, Weeks J C. Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med. 336:1997;1465-1471.
25. Grann V R, Panageos K S, Whong W, Antman K H, Neugut A. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol. 16:1998;979-985.
26. Holzman D. Prophylactic cancer surgeries offer no guarantees, uncertain outcomes. J Natl Cancer Inst. 88:1996;1428-1429.
27. Tobacman J K, Tucker M A, Kase R. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian cancer prone families. Lancet. 8302:1982;795-797.
28. Hallowell N. You don't want to lose your ovaries because you think 'I might become a man.' Women's perceptions of prophylactic surgery as a cancer risk management option. Psycho-oncology. 7:1998;263-275.
29. Kritz-Silverstein D, Barrett-Connor E, Wingard D L. Hysterectomy, oophorectomy, and heart disease risk factors in older women. Am J Public Health. 87:1997;676-680.
30. Colditz G A. Hormone replacement therapy increases the risk of breast cancer. Ann N Y Acad Sci. 833:1997;129-136.
31. Colditz G A. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst. 90:1998;814-823.
32. Ewertz M. Hormone therapy in the menopause and breast cancer risk - a review. Maturitas. 23:1996;241-246.
33. Speroff T, Dawson N V, Speroff L, Haber R J. A risk-benefit analysis of elective bilateral oophorectomy: effect of changes in compliance with estrogen therapy on outcome. Am J Obstet Gynecol. 164:1994;165-174.
34. Doren M, Schneider H P. Long-term compliance of continuous combined estrogen and progestogen replacement in postmenopausal women. Maturitas. 2:1996;99-105.
35. Lerman C, Croyle R T. Genetic testing for cancer predisposition: behavioral science issues. Monogr Natl Cancer Inst. 17:1995;63-66.
36. Vlek C. Risk assessment, risk perception and decision making about courses of action involving genetic risk: an overview of concepts and methods. Birth Defects. 23:1987;171-207.
37. Schwartz L M, Woloshin S, Black W C, Welch H G. The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med. 127:1997;966-972.
38. Merz J F, Fischoff B. Informed consent does not mean rational consent. Cognitive limitations on decision-making. J Leg Med. 11:1990;321-350.
39. Kahneman, D, Snell, J, Predictive utility, in, Hogarth, R, M, (ed), Handbook of Personality: Theory and Research, New York, Guilford, 1990, pp, 66, - 100.
40. Tversky A, Shafir E. Choice under conflict: the dynamics of deferred decision. Psychol Sci. 3:1992;358-361.
41. Lerman C, Schwartz M D, Lin T H, Hughes C, Narod S, Lynch H T. The influence of psychological distress on use of genetic testing for cancer risk. J Consult Clin Psychol. 65:1997;414-420.
42. Chaliki H, Loader S, Levenkron J C, Logan-Young W, Hall W J, Rowley P T. Women's receptivity to testing for genetic susceptibility to breast cancer. Am J Public Health. 85:1995;1133-1135.
43. Davies K, White M. Breakthrough: The Race to Find the Breast Cancer Gene. 1996;Wiley, New York.
44. Lerman, C, Psychological aspects of genetic testing for cancer susceptibility, in, Krantz, D, Baum, A, (eds), Perspectives in Behavioral Medicine, Hillsdale, NJ, Erlbaum, in press.
45. Miller S M. Monitoring and blunting of threatening information: cognitive interference and facilitation in the coping process. Sarason I G, Pierce G R, Sarason B R. Cognitive Interference: Theories, Methods, and Findings. 1997;175-190 Erlbaum, Hillsdale.
46. Miller, S, M, Diefenbach, M, A, The Cognitive-Social Health Information Processing (C-SHIP) model: a theoretical framework for research in behavioral oncology, in, Krantz, D, Baum, A, (eds), Perspectives in Behavioral Medicine, Hillsdale, NJ, Erlbaum, in press.
47. Miller S M, Mischel W, O'Leary A, Mills M. From human papillomavirus (HPV) to cervical cancer: psychological processes in infection, detection, and control. Ann Behav Med. 18:1996;219-228.
48. Miller S M, Shoda Y, Hurley K. Applying cognitive-social theory to health-protective behavior: breast self-examination in cancer screening. Psychol Bull. 119:1996;70-94.
49. Leventhal H, Diefenbach M A, Leventhal E A. Illness cognition: using common sense to understand treatment adherence and affect cognition interactions. Cog Ther Res. 16:1992;143-163.
50. Curry S J, Emmons K M. Theoretical models for predicting and improving compliance with breast cancer screening. Ann Behav Med. 16:1994;302-316.
51. Gritz E, Bastani R. Cancer prevention: behavior changes: the short and the long of it. Prev Med. 22:1993;676-688.
52. Foa E B, Kozak M J. Emotional processing of fear: exposure to corrective information. Psychol Bull. 99:1986;20-35.
53. Meichenbaum D. Stress inoculation training: a twenty year update. Woolfolk R L, Lehrer P M. Principles and Practice of Stress Management. 1992;373-406 Guilford, New York.
54. Lazarus R. Emotion and Adaptation. 1991;Plenum, New York.
55. Bandura A. Social Foundations of Thought and Action: A Social Cognitive Theory. 1986;Prentice-Hall, Englewood Cliffs.
56. Mischel W. Toward a cognitive social learning reconceptualization of personality. Psychol Rev. 80:1973;252-283.
57. Mischel W. Personality dispositions revisited and revised: a view after three decades. Pervin L. Handbook of Personality Psychology. 1990;111-134 Guilford, New York.
58. Lynch H T, Lemon S J, Durham C, Tinley S T, Connolly C, Lynch J F, Surdam J, Orinion E, Slominski-Caster S, Watson P, Lerman C, Tonin P, Lenoir G, Serova O, Narod S. A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer. 79:1997;2219-2228.
59. Lerman C, Schwartz M, Miller S M, Daly M, Sands C, Rimer B. A randomized trial of breast cancer counseling: interacting effects of counseling, educational level, and coping style. Health Psychol. 15:1996;75-83.
60. Stefanek M E, Helzlsouer K J, Wilcox P M, Houn F. Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med. 24:1995;412-419.
61. Basen-Engquist K. Ovarian cancer screening and psychosocial issues: relevance to clinical practice. Gynecol Oncol. 65:1997;195-196.
62. Stefanek M E, Wilcox P. First degree relatives of breast cancer patients: screening practices and provision of risk information. Cancer Detect Prev. 15:1991;379-384.
63. Audrain J, Schwartz M D, Lerman C, Hughes C, Peshkin B N, Biesecker B. Psychological distress in women seeking genetic counseling for breast-ovarian cancer risk: the contributions of personality and appraisal. Ann Behav Med. 19:1997;370-377.
64. Robinson G E, Rosen B P, Bradley L N, Rockert W G, Carr M L, Cole D EC, Murphy K J. Psychological impact of screening for familial ovarian cancer: reactions to initial assessment. Gynecol Oncol. 65:1997;197-205.
65. Stefanek M E. Bilateral prophylactic mastectomy: issues and concerns. Monogr Natl Cancer Inst. 17:1995;37-42.
66. Mulvihill J, Safyer A, Bennig J. Prevention in familial breast cancer: counseling and prophylactic mastectomy. Prev Med. 11:1982;500-511.
67. Miller S M. Monitoring versus blunting styles of coping with cancer influence the information patients want and need about their disease: implications for cancer screening and management. Cancer. 76:1995;167-177.
68. Lerman C, Daly M, Masny A, Balshem A. Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol. 12:1994;843-850.
69. Schwartz M D, Lerman C, Miller S M, Daly M, Masny A. Coping disposition, perceived risk, and psychological distress among women at increased risk for ovarian cancer. Health Psychol. 14:1995;232-235.
70. Lerman C, Daly M, Sands C, Balshem A, Lustbader E, Heggan T, Goldstein L, James J, Engstrom P. Psychological distress interferes with mammography adherence among women at risk for breast cancer. J Natl Cancer Inst. 85:1993;1074-1080.
71. Kash K M, Holland J C, Halper M S, Miller D G. Psychological distress and surveillance behaviors of women with a family history of breast cancer. J Natl Cancer Inst. 84:1992;24-30.
72. Wardle F J, Collins W, Pernet A L, Whitehead M I, Bourne T H, Campbell S. Psychological impact of screening for familial ovarian cancer. J Natl Cancer Inst. 85:1993;653-657.
73. Wardle J, Pernet A, Collins W, Bourne T. False positive results in ovarian cancer screening: one year follow-up of psychological status. Psychol Health. 10:1994;33-40.
74. Shoda Y, Mischel W, Miller S M, Diefenbach M A, Daly M, Engstrom P. Psychological interventions and genetic testing: facilitating informed decisions about BRCA1/2 cancer susceptibility. J Clin Psychol Med Settings. 5:1998;3-17.
75. Lerman C, Lustbader E, Rimer B, Daly M, Miller S M, Sands C, Balshem A. Effects of individualized breast cancer risk counseling: a randomized trial. J Natl Cancer Inst. 87:1995;286-292.
76. Gail M H, Brinton L A, Byar D P, Corle D K, Green S B, Schairer C, Mulvihill J J. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 81:1989;1879-1886.
77. Lerman C, Biesecker B, Benkendorf J L, Kerner J, Gomez-Caminero A, Hughes C, Reed M M. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1. J Natl Cancer Inst. 89:1997;148-157.
78. Weinstein N. Why it won't happen to me: perceptions of risk factors and susceptibility. Health Psychol. 3:1984;431-457.
79. Miller S M, Mangan C E. Interacting effects of information and coping style in adapting to gynecologic stress: Should the doctor tell all? J Personality Soc Psychol. 45:1983;223-236.
80. Miller S M, Combs C, Stoddard E. Information, coping and control in patients undergoing surgery and stressful medical procedures. Steptoe D A, Appels A. Stress, Personal Control and Health. 1989;107-130 Wiley, New York.
81. Miller S M, Buzaglo J S, Simms S L, Green V, Bales C, Mangan C E, Sedlacek T V. Monitoring styles in women at risk for cervical cancer: implications for the framing of health-relevant messages. Ann Behav Med. 21:1999;20-26.
82. Miller, S, M, Fang, C, Y, Diefenbach, M, A, Bales, C, B, Tailoring psychosocial interventions to the individual's health information processing style: the influence of monitoring versus blunting in cancer risk and disease, in, Baum, A, Andersen, B, (eds), Psychosocial Interventions and Cancer, Washington, DC, American Psychological Association, in press.
83. Lerman C. Translation behavioral research in cancer genetics. Clin Neurol Neurosurg. 26:1997;S65-S69.